Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lanreotide prolonged-release subcutaneous

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

SSTR agonist

Related drugs:

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2